64 related articles for article (PubMed ID: 3275346)
1. A promising regimen for stage IIIB breast cancer.
Madajewicz S
Oncology (Williston Park); 1987 Sep; 1(7):17. PubMed ID: 3275346
[No Abstract] [Full Text] [Related]
2. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy.
Blumenschein GR; DiStefano A; Caderao J; Fristenberg B; Adams J; Schweichler LH; Drinkard L
Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2633-7. PubMed ID: 10068266
[TBL] [Abstract][Full Text] [Related]
3. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
Seguchi T; Nakano E; Miki T; Kondoh M; Nishimura K; Nakamura N; Okuyama A
Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
[TBL] [Abstract][Full Text] [Related]
4. Treatment of high-stage bladder cancer: case for adjunctive chemotherapy.
Walther PJ
Semin Urol; 1993 May; 11(2):69-73. PubMed ID: 8362122
[No Abstract] [Full Text] [Related]
5. Phase II trial of methotrexate, vinblastine, doxorubicin, and cisplatin in advanced/recurrent carcinoma of the uterine cervix and vagina.
Long HJ; Cross WG; Wieand HS; Webb MJ; Mailliard JA; Kugler JW; Tschetter LK; Kardinal CG; Ebbert LP; Rayson S
Gynecol Oncol; 1995 May; 57(2):235-9. PubMed ID: 7729741
[TBL] [Abstract][Full Text] [Related]
6. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].
Fukuda H; Mitsumori K; Minagawa S; Kumazawa T; Tadachi K; Iinuma M; Satoh S; Satoh K; Habuchi T; Kato T
Hinyokika Kiyo; 2005 Feb; 51(2):113-6. PubMed ID: 15773365
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen.
Orlando L; Colleoni M; Curigliano G; Nolè F; Ferretti G; Masci G; Peruzzotti G; Minchella I; Intra M; Veronesi P; Viale G; Goldhirsch A
Anticancer Res; 2001; 21(6A):4135-9. PubMed ID: 11911307
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin plus vinorelbine (PVn) as a salvage regimen for refractory breast cancer.
Chehal A; Taher A; Khalil M; Shamseddine A
Breast; 2004 Oct; 13(5):421-4. PubMed ID: 15454199
[TBL] [Abstract][Full Text] [Related]
9. Impact of methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy in patients with lymph node metastases from transitional cell carcinoma of the lower urinary tract.
Koch MO; Coussens D
Semin Urol; 1993 Feb; 11(1):14-9. PubMed ID: 8465122
[No Abstract] [Full Text] [Related]
10. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium.
Long HJ; Nelimark RA; Podratz KC; Suman V; Keeney GL; Nikcevich DA; Kugler JW; Rowland KM; Kardinal CG; Wos EJ
Gynecol Oncol; 2006 Mar; 100(3):501-5. PubMed ID: 16185755
[TBL] [Abstract][Full Text] [Related]
11. Actual 5-year survival of patients with stage IIIB breast carcinoma: phase II trial of methotrexate, vinblastine, adriamycin, cisplatin, and folinic acid.
Madajewicz S; Matei D; Hentschel P; Kudelka A; Abel W; Fiore JJ; DaCosta NA; Pendyala L
Cancer Invest; 1999; 17(7):463-7. PubMed ID: 10518189
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant chemotherapy with cyclophosphamide methotrexate and 5-fluorouracil (CMF) in stage II breast cancer in Indian patients.
Shetty PA; Sarda PK; Majumdar AT; Pai VR; Shinde SR; D'Souza LJ; Pinto JM; Jussawalla DJ
Indian J Cancer; 1985 Sep; 22(3):239-44. PubMed ID: 3843327
[No Abstract] [Full Text] [Related]
13. [New chemotherapy regimens for advanced bladder cancer].
Fagbemi SO; Stadler WM
Actas Urol Esp; 1998 Jun; 22(6):548-9. PubMed ID: 9734137
[No Abstract] [Full Text] [Related]
14. Neoadjuvant chemotherapy with vinorelbine-containing regimens in elderly patients with locally advanced breast cancer.
Ma CD; Chen CM; Chen XS; Liu GY; Di GH; Wu J; Lu JS; Yang WT; Chen JY; Shao ZM; Shen ZZ; Shen KW
Anticancer Res; 2008; 28(5B):3093-7. PubMed ID: 19031963
[TBL] [Abstract][Full Text] [Related]
15. M-VAC regimen in murine bladder tumors.
Brausi M; Hickey DP; Blatnik AF; Soloway MS
J Chemother; 1989 Jul; 1(4 Suppl):1132-3. PubMed ID: 16312805
[No Abstract] [Full Text] [Related]
16. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D
Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565
[TBL] [Abstract][Full Text] [Related]
17. Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases.
Purdy MH
Can J Oncol; 1995 Dec; 5 Suppl 1():63-8. PubMed ID: 8853528
[TBL] [Abstract][Full Text] [Related]
18. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP.
Schneider J; Lucas R; Sánchez J; Ruibal A; Tejerina A; Martín M
Anticancer Res; 2000; 20(6B):4373-7. PubMed ID: 11205274
[TBL] [Abstract][Full Text] [Related]
19. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
Hudis C; Seidman A; Raptis G; Fennelly D; Gilewski T; Baselga J; Theodoulou M; Sklarin N; Moynahan M; Surbone A; Currie V; Lebwohl D; Uhlenhopp M; Crown J; Norton L
Semin Oncol; 1996 Feb; 23(1 Suppl 1):58-64. PubMed ID: 8629040
[TBL] [Abstract][Full Text] [Related]
20. Effect of tamoxifen after chemotherapy in hormone receptor-positive, node-negative breast cancer.
Panasci LC
J Clin Oncol; 2006 May; 24(15):2392; author reply 2392. PubMed ID: 16710042
[No Abstract] [Full Text] [Related]
[Next] [New Search]